Cubist Systematic Strategies LLC Acquires 9,967 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Cubist Systematic Strategies LLC increased its stake in Supernus Pharmaceuticals by 7.1%, acquiring an additional 9,967 shares, and now holds a total of 149,489 shares valued at approximately $4.9 million.
• CEO Jack A. Khattar sold 140,000 shares of Supernus stock for about $5.88 million, resulting in an 11.96% decrease in his ownership position.
• Supernus Pharmaceuticals' stock received several analyst upgrades, with Cantor Fitzgerald raising its target price from $42.00 to $46.00 and issuing an "overweight" rating.

Cubist Systematic Strategies LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 149,489 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,967 shares during the period. Cubist Systematic Strategies LLC owned 0.27% of Supernus Pharmaceuticals worth $4,896,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of SUPN. Armistice Capital LLC lifted its holdings in shares of Supernus Pharmaceuticals by 7.4% during the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after purchasing an additional 360,000 shares in the last quarter. Woodline Partners LP raised its stake in shares of Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock worth $15,326,000 after buying an additional 235,257 shares during the period. BNP Paribas Financial Markets grew its position in shares of Supernus Pharmaceuticals by 248.0% during the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after purchasing an additional 208,552 shares in the last quarter. GW&K Investment Management LLC grew its position in shares of Supernus Pharmaceuticals by 14.6% during the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock worth $45,275,000 after purchasing an additional 176,091 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in Supernus Pharmaceuticals by 33.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock valued at $19,731,000 after buying an additional 136,870 shares in the last quarter.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, CFO Timothy C. Dec sold 11,780 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares of the company's stock, valued at approximately $55,434.54. This represents a 90.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.51, for a total value of $623,140.00. Following the sale, the senior vice president owned 15,496 shares of the company's stock, valued at approximately $689,726.96. The trade was a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 235,184 shares of company stock worth $10,174,149. Corporate insiders own 8.80% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Piper Sandler lifted their price target on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

Supernus Pharmaceuticals Price Performance

Shares of SUPN traded down $0.16 during midday trading on Tuesday, reaching $45.67. 143,265 shares of the stock were exchanged, compared to its average volume of 636,696. The business's 50-day moving average price is $38.29 and its 200 day moving average price is $34.24. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $46.78. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of 39.63 and a beta of 0.79.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.